Singapore, May 1 -- China-based startup Huahui Health has entered into a global exclusive option, license and collaboration agreement with BeOne Medicines for HH160, a novel trispecific antibody in oncology immunotherapy.

Under the agreement, BeOne Medicines is granted an exclusive option covering the development, manufacturing, and commercialisation of HH160 worldwide.

Pursuant to the agreement, BeOne Medicines will pay Huahui Health an upfront payment of $20 million. Upon exercise of the option by BeOne Medicines, Huahui Health will be entitled to receive an additional $100 million option exercise payment.

Subject to the achievement of development, regulatory and sales milestones, Huahui Health is eligible to receive milestone paymen...